Pro-inflammatory autoreactive T lymphocytes specific for cartilage-associated antigens play a pivotal role in the development of rheumatoid arthritis. Standard treatment of rheumatoid arthritis is based on nonsteroidal anti-inflammatory drugs (NSAIDs), nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) and non-specific (non-selective) immunosuppressants (hormones, cytostatic agents and others). This treatment fails to interrupt the underlying immunopathological events and is often associated with serious complications.

T-cell autovaccination-based technology is aimed to stimulate patient’s immune responses, which selectively inactivate pathogenic self-reactive Т lymphocytes.
Forty-two patients (age 28–58 y; 37 women, 5 men) with rheumatoid arthritis (disease history ≥2 years) were subjected to the T-cell vaccination treatment. Our clinical data (Table 1) showed that T cell vaccination of rheumatoid arthritis patients (n = 42) resulted in apparent clinical improvements over a 2 year follow-up .

Table 1. Clinical parameters of rheumatoid arthritis patients.

ParameterFollow-up time (months)
 0 (n=42) 3 (n=42) 6 (n=42) 12 (n=42) 18 (n=32) 24 (n=22)
 COE (mm/h) 38.41±2.20 31.12±1.94** 22.81±1.26** 21.75±1.60** 20.19±1.74** 21.14±2.12**
 Hb (g/L) 107.80±1.45 113.70±1.25** 120.81±1.01** 125.20±0.98** 126.42±1.17** 126.46±1.88**
 DAS 28 5.92±0.13 4.93±0.16** 3.34±0.18** 2.99±0.17** 2.96±0.21** 3.12±0.27**

In conclusion. rheumatoid arthritis patients with early and advanced stages of the disease can obtain significant clinical benefits due to the application of autologous T cell vaccination.